TY  - CHAP
M1  - Book, Section
TI  - Tamoxifen Pharmacogenetics
A1  - Zembutsu, Hitoshi
A1  - Nakamura, Yusuke
A2  - Murray, Michael F.
A2  - Babyatsky, Mark W.
A2  - Giovanni, Monica A.
A2  - Alkuraya, Fowzan S.
A2  - Stewart, Douglas R.
PY  - 2014
T2  - Clinical Genomics: Practical Applications in Adult Patient Care
AB  - Drug  summary:Tamoxifen  is  widely  used  antiestrogen  therapy  for  pre-  and  postmenopausal  women  with  metastatic  breast  cancer,  for  prevention  of  recurrence  as  adjuvant  therapy,  and  for  women  with  a  high  risk  of  developing  breast  cancer  as  chemoprevention.Five  years  of  adjuvant  tamoxifen  safely  reduces  15-year  risks  of  breast  cancer  recurrence.The  most  frequent  adverse  events  by  tamoxifen  treatment  is  hot  flash  (>60%).  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1102698622
ER  -